Yuhan Corporation’s ‘IgE Trap; YH35324’ Surpasses ‘Xolair’ in Phase 1 Trials, Delivering Superior IgE Suppression in High IgE Patients (biospectator.com)
Yuhan Corporation’s ‘IgE Trap; YH35324’ Surpasses ‘Xolair’ in Phase 1 Trials, Delivering Superior IgE Suppression in High IgE Patients YH35324 is an Fc fusion protein of the IgE series, ‘IgE Trap’, which is a form that fuses the extracellular domain of the IgE receptor (FcεR1) with a hybrid Fc. Its main mechanism of action is […]
‘Amivantamab’ and ‘Lazertinib’ Combination Treatment Shows Extended PFS as First-line of Therapy in NSCLC
Yuhan Corporation’s 3rd generation EGFR TKI, ‘Lazertinib’, has taken another step towards its global blockbuster aspirations.This achievement comes as a result of successful outcomes in the clinical trial named ‘MARIPOSA,’ in which Janssen evaluated the anti-cancer drug ‘Amivantamab’ in combination with ‘Lazertinib’ compared to AstraZeneca’s ‘Osimertinib’. According to industry reports on October 2nd, Janssen, a […]
Yuhan and Cyrus Therapeutics signed an agreement for Joint Research on Anti-Cancer Target Therapeutics
Yuhan announced that it has signed an MOU with Cyrus Therapeutics to develop a small molecule anti-cancer target therapy. Cyrus Therapeutics is a Korean biotechnology company with small molecule therapeutics and targeted proteolysis (TPD) technology that degrades protein and removes cancer cells. Through the agreement, the two companies plan to cooperate in the fields of […]
Yuhan Corporation Announces Free Supply of Its New Lung Cancer Drug “Lazertinib” Until Covered by Insurance through Expanded Access Program (EAP) in South Korea
Yuhan Corporation, a leading pharmaceutical company, has announced that it will provide its newly developed drug, “Lazertinib,” as a first-line treatment for free until it is covered by health insurance in South Korea. This initiative is in line with the company’s commitment to giving back to society, a value that was cherished by its late […]
Business Development Manager Position Opening
Yuhan USA Corporation– 유한양행 미국 법인 Work locations: San Diego, CA or Boston, MA Employee type: Full-time Visa Sponsorship available: No Contact Information: info@yuhan-usa.com 유한USA는 96년의 전통을 가진 한국 최대 제약회사 중 하나인 유한양행의 미국 법인으로 유한양행이 글로벌 제약사로 발돋움 하기 위한 세계화 전략의 전초기지로서 사업 개발 및 신약 개발 협업의 기회를 함께할 인재를 찾고 […]
Yuhan Corporation confirms efficacy of Lazertinib, a new drug for NSCLC in Phase 3 trial
The top line results for the phase 3 clinical trial of the 3rd generation EGFR TKI ‘Lazertinib’ being developed by Yuhan Corporation have been announced. The results confirmed the efficacy of Lazertinib as a first-line treatment and Yuhan Corporation plans to submit an application for approval to expand indications in South Korea in Q1 of […]
PCS12852 Improves Gastric Emptying in Gastroparesis Patients
Processa Pharmaceuticals announced that positive gastric emptying results from its PCS12852 Phase 2A Proof-of-Concept trial in patients with moderate to severe gastroparesis. PCS12852 is a novel, potent, and highly selective 5-hydroxytryptamine-4 (5-HT4) receptor agonist, originally developed by Yuhan Corporation in South Korea, and exclusively licensed to Processa Pharmaceuticals in August 2020 (https://bit.ly/30iKnMR). This Phase 2A […]
Yuhan’s ‘Lazertinib’ Phase 3 topline data shows ‘PFS Improvement’ as first line of therapy
On 14 October, Yuhan announced top-line Phase 3 study data of Lazertinib as 1st line treatment that has significantly improved progression-free survival (PFS) as the primary endpoint. LASER301, comparing Lazertinib for the primary treatment of EGFR mutated non-small cell lung cancer (NSCLC) with the standard therapeutic agent gefitinib (Brand: Iressa), shows the risk of stage […]
[Job Opening] Business Development Manager – Boston office
[채용 공고]유한양행 미국 법인 – 유한 USA Position:Business Development Manager Work location:Boston, MA Responsibilities:1.개방형 기술혁신 및 In/Out Licensing Partnering 사업개발2.유망 바이오 기업 발굴 및 전략적 투자활동3.신약개발 연구 및 바이오 파마 동향 정보 수집 Qualifications: (Required)1.해외 제약사/바이오텍 근무 혹은 그에 준하는 경력2.영주권 또는 시민권 소지자3.영어 능통4.신약 개발 관련 전공 분야 석사 이상 Qualifications: (Preferred)1.해외 제약사 사업개발(Business […]
Yuhan Corporation to create a state-of-the-art R&D cluster in Gunpo-City, South Korea
Yuhan Corporation is working together with Gunpo City, South Korea to create a high-tech bio research base and CMC center in the industrial area of Dangjeong-dong, Gunpo. Yuhan Corporation will make an investment of approximately 80 billion Won ($66.7M USD) towards the bio research center and CMC center project. Through the establishment of this bio […]